Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 9/20 | 0.73 |
| ▸ | RORC | P51449 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | CFTR | P13569 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915492 | 0.86 | MAPT (0.96) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5453576 | 0.85 | FLT3 (1.00) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23850639 | 0.84 | RORC (1.00) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15281386 | 0.81 | ALDH1A1 (1.00) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5457779 | 0.81 | RAB9A (1.00) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5457818 | 0.80 | FLT3 (1.00) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15281367 | 0.80 | ALDH1A1 (0.98) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5453533 | 0.79 | FLT3 (0.67) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5458447 | 0.76 | ALDH1A1 (0.68) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12768285 | 0.76 | RAB9A (0.61) | RAB9AMAPTNPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1294707-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2001098290-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | HUTCHINSON FRED CANCER RES (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | HUTCHINSON FRED CANCER RES (US) | 2017-10-26 | — | — | US | disclosed |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-07 | — | — | US | disclosed |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-07 | — | — | US | disclosed |
| WO-2013142628-A2 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | RAB9A 948/4885MAPT 21/4885NPC1 2627/4885 |
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | BLM, DNA2, DCLRE1B | RAB9A 2030/4885MAPT 3731/4885NPC1 2212/4885 |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | BLM, DNA2, DCLRE1B | RAB9A 2030/4885MAPT 3731/4885NPC1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.